There is plenty of evidence to show that testosterone replacement therapy increases the risk for hear attacks, a cardiologist told an Illinois federal jury during the first trial among thousands in a multi district litigation alleging Abbie’s AndroGel causes heart risks, Law360 reports.
Dr. Hossein Ardehali, a cardiologist at Northwestern University’s Feinberg School of Medicine, is an expert witness testifying for plaintiff Jesse Mitchell. Dr. Ardehali told jurors that he reviewed several studies involving men who took AndroGel and concluded that there was sufficient evidence to show the testosterone treatment increases cardiovascular risks.
For example, he pointed to a 2010 study involving older men treated with testosterone to determine if it improved their mobility. The study was halted by a safety monitoring board because a number of the participants suffered cardiac events. Another study in 2013, tested testosterone in men who had previous cardiac catheterization procedures, and thus a documented heart history before taking the medication. The study showed a 29 percent increase in heart risk.
Dr. Ardehaili said that he also reviewed 17 cases of men who used AndroGel who reported to AbbVie that they suffered some form of heart problem. He also believes that the testosterone treatment also caused Jesse Mitchell’s 2012 heart attack. Mitchell sued AbbVie in 2014. His case is one of more than 4,000 waged against AbbvVie and other manufacturers of testosterone treatments. AbbVie is facing the first trials in the MDL since it is by far the top selling testosterone treatment.
Mitchell’s lawsuit also slams AbbVie for marketing AndroGel directly to consumers for off-label use, to treat symptoms of a condition called Low T such as low libido, muscle loss and mood swings. The medication is only FDA approved to treat hypogonadism, a condition in which men produce too little of the male hormone due to injury or disease.